CSE Bulletin: Consolidation - BioVaxys Technology Corp.

CSE Bulletin: Consolidation - BioVaxys Technology Corp.

BioVaxys Technology Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares.

As a result, the number of outstanding shares will be reduced to approximately 29,342,496 common shares.

The name and symbol will not change.

Please note that all open orders will be canceled at the close of business on September 10, 2025. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

BioVaxys Technology Corp. a annoncé une consolidation de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-consolidée pour dix (10) actions ordinaires pré-consolidées.

En conséquence, le nombre d'actions en circulation sera réduit à environ 29 342 496 actions ordinaires.

Le nom et le symbole ne changeront pas.

Veuillez noter que toutes les commandes ouvertes seront annulées à la fermeture des bureaux le 10 septembre 2025. Les négociants sont invités à ressaisir leurs commandes en tenant compte de la consolidation des actions.

Trading on a Consolidated Basis/Négociation sur une Base Consolidée : Le 11 SEPT 2025
Record Date/Date d'Enregistrement : Le 11 SEPT 2025
Anticipated Payment Date/Date de Paiement Prévue : Le 11 SEPT 2025
Symbol/Symbole : BIOV
NEW/NOUVEAU CUSIP : 09076M 20 0
NEW/NOUVEAU ISIN : CA 09076M 20 0 4
Old/Vieux CUSIP & ISIN : 09076M101/CA09076M1014

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

BIOV:CNX
The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News